Seek Returns logo

DXCM vs. VTRS: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at DXCM and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolDXCMVTRS
Company NameDexCom, Inc.Viatris Inc.
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Equipment & SuppliesPharmaceuticals
Market Capitalization32.03 billion USD12.42 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateApril 14, 2005March 17, 1980
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of DXCM and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

DXCM vs. VTRS: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolDXCMVTRS
5-Day Price Return2.14%-0.37%
13-Week Price Return-6.08%21.58%
26-Week Price Return-2.88%-1.39%
52-Week Price Return5.12%-9.97%
Month-to-Date Return1.11%21.85%
Year-to-Date Return5.01%-14.46%
10-Day Avg. Volume3.24M11.82M
3-Month Avg. Volume3.66M12.30M
3-Month Volatility35.91%32.62%
Beta1.500.89

Profitability

Return on Equity (TTM)

DXCM

25.62%

Health Care Equipment & Supplies Industry

Max
34.53%
Q3
19.38%
Median
9.52%
Q1
4.86%
Min
-7.58%

In the upper quartile for the Health Care Equipment & Supplies industry, DXCM’s Return on Equity of 25.62% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

VTRS

-19.92%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

DXCM vs. VTRS: A comparison of their Return on Equity (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

DXCM

13.29%

Health Care Equipment & Supplies Industry

Max
23.34%
Q3
13.06%
Median
9.53%
Q1
5.96%
Min
-3.87%

A Net Profit Margin of 13.29% places DXCM in the upper quartile for the Health Care Equipment & Supplies industry, signifying strong profitability and more effective cost management than most of its peers.

VTRS

-24.57%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

DXCM vs. VTRS: A comparison of their Net Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

DXCM

15.98%

Health Care Equipment & Supplies Industry

Max
29.44%
Q3
17.80%
Median
13.95%
Q1
8.73%
Min
-3.56%

DXCM’s Operating Profit Margin of 15.98% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.

VTRS

-26.54%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

DXCM vs. VTRS: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolDXCMVTRS
Return on Equity (TTM)25.62%-19.92%
Return on Assets (TTM)8.49%-8.50%
Net Profit Margin (TTM)13.29%-24.57%
Operating Profit Margin (TTM)15.98%-26.54%
Gross Profit Margin (TTM)60.01%40.15%

Financial Strength

Current Ratio (MRQ)

DXCM

1.52

Health Care Equipment & Supplies Industry

Max
4.90
Q3
3.05
Median
2.14
Q1
1.49
Min
0.86

DXCM’s Current Ratio of 1.52 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.

VTRS

1.37

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

DXCM vs. VTRS: A comparison of their Current Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

DXCM

0.97

Health Care Equipment & Supplies Industry

Max
1.49
Q3
0.71
Median
0.45
Q1
0.14
Min
0.00

DXCM’s leverage is in the upper quartile of the Health Care Equipment & Supplies industry, with a Debt-to-Equity Ratio of 0.97. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

VTRS

0.82

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

DXCM vs. VTRS: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

DXCM

978.00

Health Care Equipment & Supplies Industry

Max
58.29
Q3
25.56
Median
9.06
Q1
3.60
Min
-28.92

With an Interest Coverage Ratio of 978.00, DXCM demonstrates a superior capacity to service its debt, placing it well above the typical range for the Health Care Equipment & Supplies industry. This stems from either robust earnings or a conservative debt load.

VTRS

-0.13

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

DXCM vs. VTRS: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolDXCMVTRS
Current Ratio (MRQ)1.521.37
Quick Ratio (MRQ)1.320.65
Debt-to-Equity Ratio (MRQ)0.970.82
Interest Coverage Ratio (TTM)978.00-0.13

Growth

Revenue Growth

DXCM vs. VTRS: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

DXCM vs. VTRS: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

DXCM

0.00%

Health Care Equipment & Supplies Industry

Max
4.05%
Q3
1.76%
Median
0.71%
Q1
0.00%
Min
0.00%

DXCM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

VTRS

4.58%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

DXCM vs. VTRS: A comparison of their Dividend Yield (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

DXCM

0.00%

Health Care Equipment & Supplies Industry

Max
160.00%
Q3
72.47%
Median
27.49%
Q1
0.00%
Min
0.00%

DXCM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

VTRS

137.04%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.

DXCM vs. VTRS: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolDXCMVTRS
Dividend Yield (TTM)0.00%4.58%
Dividend Payout Ratio (TTM)0.00%137.04%

Valuation

Price-to-Earnings Ratio (TTM)

DXCM

55.71

Health Care Equipment & Supplies Industry

Max
73.48
Q3
51.69
Median
34.31
Q1
25.74
Min
11.47

A P/E Ratio of 55.71 places DXCM in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

VTRS

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for VTRS is currently unavailable.

DXCM vs. VTRS: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

DXCM

7.40

Health Care Equipment & Supplies Industry

Max
9.53
Q3
5.26
Median
3.39
Q1
2.13
Min
0.00

DXCM’s P/S Ratio of 7.40 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

VTRS

0.88

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

DXCM vs. VTRS: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

DXCM

13.30

Health Care Equipment & Supplies Industry

Max
10.85
Q3
5.98
Median
3.48
Q1
2.43
Min
0.69

At 13.30, DXCM’s P/B Ratio is at an extreme premium to the Health Care Equipment & Supplies industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

VTRS

0.67

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

DXCM vs. VTRS: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Equipment & Supplies and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolDXCMVTRS
Price-to-Earnings Ratio (TTM)55.71--
Price-to-Sales Ratio (TTM)7.400.88
Price-to-Book Ratio (MRQ)13.300.67
Price-to-Free Cash Flow Ratio (TTM)55.787.29